Ultrafiltration for acute decompensated heart failure

Expert Review of Medical Devices

Volumn 2, Issue 6, 2005, Pages 689-697

  Boyle, Andrew ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Diuresis; Diuretic resistance; Heart failure; Natriuresis; Ultrafiltration

Indexed keywords

AQUADEX; BIOLOGICAL MARKER; DIURETIC AGENT; ELECTROLYTE; GLYCERYL TRINITRATE; HEPARIN; INOTROPIC AGENT; MAGNESIUM; NATRIURETIC FACTOR; NESIRITIDE; NITROGEN; POTASSIUM; SODIUM; UREA; VASODILATOR AGENT; WATER;

ACCURACY; ANTICOAGULATION; CARDIOVASCULAR EQUIPMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEVICE INFECTION; DIALYSIS; DIURESIS; DIURETIC THERAPY; DOSE RESPONSE; ELECTROLYTE BLOOD LEVEL; FEASIBILITY STUDY; FEEDBACK SYSTEM; HEALTH CARE COST; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FILLING; HEART VENTRICLE OVERLOAD; HEART VOLUME; HEMOCONCENTRATION; HEMOFILTRATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION RISK; INTERMETHOD COMPARISON; INTERSTITIAL FLUID; INTRAVENOUS CATHETER; LENGTH OF STAY; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; METHODOLOGY; MORBIDITY; NATRIURESIS; NEPHROTOXICITY; PARTIAL THROMBOPLASTIN TIME; POTASSIUM BLOOD LEVEL; PREDICTION; RECURRENT DISEASE; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SAFETY; SODIUM BLOOD LEVEL; STARLING LAW; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 28244473664     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2.6.689     Document Type: Review

References (32)

1. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur. J. Heart Fail. 1(3), 251-257 (1999).
2. Nohria A, Sui WT, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J. Am. Coll. Cardiol. 41(10), 1797-1804 (2003).
3. Brater DC. Diuretic therapy. N. Engl. J. Med. 339(6), 387-339 (1998).
4. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin. Pharmacokinet. 30(3), 229-249 (1996).
5. Stanton BA. Adaptation of distal tubule and collecting duct to increased Na delivery. Am. J. Physiol. 255, F1269-F1275 (1988).
6. Neuberg GW, Miller AB, O'Connor CM et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J. 144(1), 31-38 (2002).
7. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br. Heart J. 57(1), 17-22 (1987).
8. Francis GS, Siegel RM, Goldsmith SR et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann. Int. Med. 103(1), 1-6 (1985).
9. Agostini PG, Marenzi GC, Lauri CF et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am. J. Med. 96, 191-199 (1994).
10. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1(8593), 1033-1035 (1988).
11. Marenzi GC, Lauri G, Grazi M et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J. Am. Coll. Cardiol. 38(4), 963-968 (2001).
12. Cuffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. J. Am. Med. Assoc. 287(12), 1541-1547 (2002).
13. McCurley JM, Hanlon SU, Wei SK, Wedam AF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J. Am. Coll. Cardiol. 44(6), 1301-1307 (2004).
14. Butler J, Forman DE, Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J. 147(2), 331-338 (2004).
15. Hillege HL, Girbes ARJ, De Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102(2), 203-210 (2000).
16. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerine in patients with decompensated heart failure. Am. J. Cardiol. 93, 237-240 (2004).
17. Publication Committee for the VMAC Investigators. J. Am. Med. Assoc. 287(12), 1531-1540 (2002).
18. Sackner-Bernstein JD, Skopicki HA, Aaronson KD, Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111, 1487-1491 (2005).
19. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson KD. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. J. Am. Med. Assoc. 293(15), 1900-1905 (2005).
20. Wang DJ, Dowling TC, Meadows D et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110, 1620-1625 (2004).
21. Peacock WF, Emerman CL. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients - the PROACTION trial. J. Am. Coll. Cardiol. 41(Suppl. 6A), 336A (2003).
22. Agostoni PG, Marenzi GC, Pepi M et al. Isolated ultrafiltration in moderate congestive heart failure. J Am. Coll. Cardiol. 21(2), 424-431 (1993).
23. Fonarow GC, Stevenson LW, Steimle AE et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure. Circulation 90(2), 1488 (1994).
24. Lucas C, Johnson W, Hamilton MA et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am. Hears J. 140(6), 840-847 (2000).
25. Jaski BE, Ha J, Denys BG et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card. Fail. 9(3), 227-231 (2003).
26. Bart BA, Boyle AJ, Bank AJ et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: relief for acutely fluid overloaded patients with decompensated congestive heart failure - the RAPID - heart failure Trial. J. Card. Fail. 10(4 Suppl.), S23 (2004).
27. Costanzo MR, Saltzberg M, O'Sullivan J et al. EUPHORIA: early ultrafiltration in patients with decompensated heart failure and observed resistance to intervention with diuretic agents. J. Card Fail. 10(4 Suppl.), S78 (2004).
28. Marenzi G, Grazi S, Giraldi F et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am. J. Med. 94(1), 49-56 (1993).
29. Canaud B, Leblanc M, Leray-Moragueus H et al. Slow continuous and daily ultrafiltration for refractory congestive heart failure. Nephrol. Dial. Transpl. 13(Suppl. 4), 51-55 (1998).
30. Asaba H, Bergstrom J, Furst P, Shaldon S, Wiklund S. Treatment of diuretic resistant fluid retention with ultrafiltration. Acta Med. Scand. 204(3), 145-148 (1978).
31. Rimondini A, Cipolla CM, Della Bells P et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am. J. Med 83, 43-47 (1987).
32. Sheppard R, Panyon J, Pohwani AL et al. Intermittent out-patient ultrafiltration for the treatment of severe refractory congestive heart failure. J. Card. Fail. 10(5), 380-3383 (2004).